04625nam 2201213z- 450 9910619467203321202210253-0365-5281-2(CKB)5670000000391602(oapen)https://directory.doabooks.org/handle/20.500.12854/93194(oapen)doab93194(EXLCZ)99567000000039160220202210d2022 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierBrain-Targeted Drug DeliveryMDPI - Multidisciplinary Digital Publishing Institute20221 online resource (260 p.)3-0365-5282-0 Brain diseases currently affect one in six people worldwide; they include a wide range of neurological diseases, from Alzheimer's and Parkinson's diseases to epilepsy, brain injuries, brain cancer, neuroinfections, and strokes. The treatment of these diseases is complex and limited due to the presence of the blood-brain barrier (BBB), which covers the entirety of the brain. The BBB not only has the function of protecting the brain from harmful substances; it is also a metabolic barrier and a transport regulator of nutrients/serum factors/neurotoxins. Knowing these characteristics when it comes to the treatment of brain diseases makes it easier to understand the lack of efficacy of therapeutic drugs, resulting from the innate resistance of the BBB to permeation. To overcome this limitation, drug delivery systems based on nanotechnology/microtechnology have been developed. Brain-targeted drug delivery enables targeted therapy with a higher therapeutic efficacy and fewer side effects because it targets moieties present in the drug delivery systems.Technology: general issuesbicssc3D cell culture systemsacetaminophenAlzheimer's diseaseAlzheimer's disease-relevant tau speciesanti-tau and anti-receptor bispecific monoclonal antibodiesblood-brain barrierblood-brain barrierbrain biodistributionbrain cancerbrain targeted therapycentral composite rotatable designcerebral open flow microperfusioncerebrospinal fluid microcirculationchemoattractantclaudin-5CNS drug deliveryconvection-enhanced deliveryCXCLCXCRdelivery to braindepressiondiffuse midline gliomadrug deliverydrug delivery into the brainelectrochemical biosensorsGB-13gene therapyglioblastomaglioblastoma multiformeglycol chitosanhigh-grade gliomahyaluronidaseIL-13IL-13Rα2IL13.E13K-PE4Eimmunotherapyimmunotoxinimproved memoryinteractions between Aβ and tauintranasal deliverylaserliposomemacromoleculesmemory impairmentmicrodialysismicroparticlesmovement impairmentn/ananoparticlenanoparticlesnanostructured lipid carriernaringeninnasal delivery systemneurosurgerynon-human primatenose to brain deliveryopioidsoptogeneticsParkinson's diseasephospholipid oily gelPLGApolyplexespomegranate seed oilreceptor expressionseizuretargeted therapytau clearance in microgliatau clearance in neuronstemporal-spatial pathological Aβ and tau distributiontight junctiontolcaponetransendothelium based on receptor-mediated transcytosisultrasoundTechnology: general issuesSousa Fláviaedt1323094Sousa FláviaothBOOK9910619467203321Brain-Targeted Drug Delivery3035376UNINA